Related Experiment Videos
Heart failure and personalized medicine
Luisa Mestroni1, Marco Merlo, Matthew R G Taylor
1University of Colorado Cardiovascular Institute, Aurora, Colorado, USA. luisa.mestroni@ucdenver.edu
Journal of Cardiovascular Medicine (Hagerstown, Md.)
|September 4, 2010
Summary
Personalized medicine leverages genomic data for tailored heart failure diagnosis and treatment. Understanding genetic variations in cardiomyopathies and drug responses optimizes patient care and outcomes.
Area of Science:
- Cardiology
- Genomics
- Personalized Medicine
Background:
- Heart failure management is evolving with personalized medicine approaches.
- Genomic information offers potential for improved diagnosis, prevention, and therapy.
- Current understanding includes monogenic disorders, modifier genes, and pharmacogenomics.
Purpose of the Study:
- To review the personalized management of heart failure.
- To discuss the roles of monogenic disorders, modifier genes, and pharmacogenomics.
- To highlight the potential of genomic data in optimizing heart failure care.
Main Methods:
- Review of current literature on personalized medicine in heart failure.
- Discussion of genetic factors including cardiomyopathies, modifier genes, and pharmacogenomics.
- Exploration of technological advancements and their clinical implications.
Main Results:
- Monogenic cardiomyopathies have established diagnostic and therapeutic guidelines.
- Common genetic variants in pathways like renin-angiotensin-adrenergic influence heart failure susceptibility and outcomes.
- Pharmacogenomic variants in receptors significantly alter treatment response in heart failure patients.
Conclusions:
- Personalized medicine, driven by genomic insights, promises to optimize heart failure management.
- Further research using high-throughput technologies will identify novel modifier genes for prognosis and therapeutics.
- Clinicians must adapt diagnostic paradigms and integrate genomic data for effective patient care and education.
Related Concept Videos
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...